Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MEIP 
MEI Pharma Inc (MEIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: MEIP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.02% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.98M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta -0.01 | 52 Weeks Range 1.46 - 4.50 | Updated Date 07/17/2025 |
52 Weeks Range 1.46 - 4.50 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.23% | Return on Equity (TTM) -89.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -18756201 | Price to Sales(TTM) 0.27 |
Enterprise Value -18756201 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 6662860 | Shares Floating 4938576 |
Shares Outstanding 6662860 | Shares Floating 4938576 | ||
Percent Insiders 1.31 | Percent Institutions 40.16 |
Upturn AI SWOT
MEI Pharma Inc
Company Overview
History and Background
MEI Pharma, Inc., founded in 2000, is a pharmaceutical company focused on the development of cancer therapies. Initially focused on cancer metabolism, it has evolved to target cancer signaling pathways. The company is based in San Diego, California.
Core Business Areas
- Hematologic Malignancies: Focuses on developing therapies for blood cancers, including lymphomas and multiple myeloma.
- Solid Tumors: Involves research and development of treatments for various solid tumor cancers.
Leadership and Structure
Daniel Gold, Ph.D. is the current President and CEO. The company has a typical pharmaceutical organizational structure, with departments focusing on research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Voruciclib: An oral CDK9 inhibitor being developed for hematologic malignancies. It is currently in clinical trials. Market share data is not yet available as the product is not yet commercialized. Competitors include companies developing other CDK9 inhibitors and therapies for similar indications like lymphoma (e.g., AbbVie, Roche).
- ME-344: A mitochondrial inhibitor being evaluated in solid tumors. Market share data is not yet available as the product is not yet commercialized. Competitors include companies developing other mitochondrial inhibitors and therapies for similar indications (e.g., Pfizer, Merck).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially the oncology segment, is highly competitive and characterized by significant research and development costs, stringent regulatory requirements, and patent protection. The market is driven by aging populations and increasing cancer incidence worldwide.
Positioning
MEI Pharma is a small to mid-sized biotechnology company focused on developing novel cancer therapies. Its competitive advantage lies in its focus on specific targets like CDK9 and mitochondrial metabolism, offering potential new mechanisms of action compared to existing therapies.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. MEI Pharma's positioning is based on developing niche products within specific cancer subtypes, allowing it to potentially capture a significant portion of the market within those targeted areas.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for differentiated mechanisms of action
- Experienced management team
- Strategic collaborations and partnerships
- Focused pipeline on hematologic and solid tumors
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- No currently marketed products generating revenue
- High risk associated with drug development
Opportunities
- Potential for accelerated regulatory pathways for novel cancer therapies
- Increasing prevalence of cancer and unmet medical needs
- Partnering opportunities with larger pharmaceutical companies
- Expanding pipeline through acquisitions or in-licensing
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established therapies
- Patent expirations and generic entry
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- MRK
Competitive Landscape
MEI Pharma faces significant competition from larger pharmaceutical companies with greater resources and established market presence. The company's success depends on differentiating its products through efficacy, safety, and novel mechanisms of action.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is primarily driven by the progression of its drug candidates through clinical trials. Major clinical milestones could trigger financial benefits.
Future Projections: Future growth is contingent on the success of voruciclib and ME-344. Analyst projections would depend on the outcome of these clinical trials.
Recent Initiatives: Recent company initiatives include advancing clinical trials of its lead candidates and seeking strategic partnerships to support development and commercialization.
Summary
MEI Pharma is a high-risk, high-reward biotechnology company with a focused pipeline of cancer therapies. Its strength lies in its novel drug candidates, but it faces challenges related to funding, clinical trial success, and competition. Potential investors must consider the company's stage of development and inherent risks associated with drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share percentages are estimates and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MEI Pharma Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2003-12-19 | Acting CEO, CFO & Corporate Secretary Mr. Justin J. File CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://meipharma.com |
Full time employees 28 | Website https://meipharma.com | ||
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.